Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Strickler

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
Cancer Discovery|June 3, 2018
<i>EGFR</i> Amplification as a Target in Gastroesophageal Adenocarcinoma: Do Anti-EGFR Therapies Deserve a Second Chance?John H Strickler
Journal of Gastrointestinal Oncology|October 18, 2016
Clinical applications of liquid biopsies in gastrointestinal oncologyJason Zhu, John H Strickler
The Oncologist|April 6, 2012
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancerJohn H Strickler, Herbert I Hurwitz
Drugs|December 18, 2023
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough TherapiesBennett A Caughey, John H Strickler
Current Oncology Reports|December 3, 2013
Palliative treatment of metastatic colorectal cancer: what is the optimal approach?John H Strickler, Herbert I Hurwitz
Optics Letters|September 29, 2009
Three-dimensional optical data storage in refractive media by two-photon point excitationJ H Strickler, W W Webb
Annual Review of Medicine|January 27, 2021
Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal CancerVan K Morris, John H Strickler
Future Oncology (London, England)|November 9, 2023
A study to learn how well tucatinib plus trastuzumab works for treating participants with metastatic colorectal cancer, and how safe it is: a plain language summary of the MOUNTAINEER studyJohn H Strickler, Tanios S Bekaii-Saab
Annals of Epidemiology|November 1, 1995
Problems in interpreting HIV sentinel seroprevalence studiesH Strickler, D R Hoover, R Dersimonian
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?John H Strickler, Brent A Hanks, Mustafa Khasraw
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
Cancer Discovery|June 3, 2018
<i>EGFR</i> Amplification as a Target in Gastroesophageal Adenocarcinoma: Do Anti-EGFR Therapies Deserve a Second Chance?John H Strickler
Journal of Gastrointestinal Oncology|October 18, 2016
Clinical applications of liquid biopsies in gastrointestinal oncologyJason Zhu, John H Strickler
The Oncologist|April 6, 2012
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancerJohn H Strickler, Herbert I Hurwitz
Drugs|December 18, 2023
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough TherapiesBennett A Caughey, John H Strickler
Current Oncology Reports|December 3, 2013
Palliative treatment of metastatic colorectal cancer: what is the optimal approach?John H Strickler, Herbert I Hurwitz
Optics Letters|September 29, 2009
Three-dimensional optical data storage in refractive media by two-photon point excitationJ H Strickler, W W Webb
Annual Review of Medicine|January 27, 2021
Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal CancerVan K Morris, John H Strickler
Future Oncology (London, England)|November 9, 2023
A study to learn how well tucatinib plus trastuzumab works for treating participants with metastatic colorectal cancer, and how safe it is: a plain language summary of the MOUNTAINEER studyJohn H Strickler, Tanios S Bekaii-Saab
Annals of Epidemiology|November 1, 1995
Problems in interpreting HIV sentinel seroprevalence studiesH Strickler, D R Hoover, R Dersimonian
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?John H Strickler, Brent A Hanks, Mustafa Khasraw
Pageof 10